SEC Form 4 · accession 0000899243-17-017790
AVEO PHARMACEUTICALS INC · AVEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew D Dallas
Officer — Chief Financial Officer
Period of report
Jul 3, 2017
Accepted (ET)
Jul 5, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001325879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.22 | Jul 3, 2017 | A | 500,000 | A | — | Jul 3, 2027 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F125% of this option shall vest on June 1, 2018, and the remainder of this option shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Company.